Compare NHS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHS | FHTX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.5M | 247.1M |
| IPO Year | N/A | 2020 |
| Metric | NHS | FHTX |
|---|---|---|
| Price | $7.23 | $4.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.86 |
| AVG Volume (30 Days) | 111.8K | ★ 185.9K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 13.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,518,000.00 |
| Revenue This Year | N/A | $47.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.95 | $2.95 |
| 52 Week High | $9.17 | $6.79 |
| Indicator | NHS | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 47.41 |
| Support Level | $7.22 | $4.33 |
| Resistance Level | $7.34 | $4.59 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 41.98 | 20.00 |
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.